Harbinger Health
Harbinger Health is a Cambridge-based biotechnology company developing blood-based multi-cancer detection tests (RESOLVE™) that use cfDNA methylation analysis and deep learning to resolve diagnostic uncertainty in symptomatic patients aged 45 and older. The company operates a CLIA-certified laboratory and plans commercial launch in H2 2026.
- Company typePrivate
- Founded2020
- HeadquartersCambridge, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Harbinger Health does
Harbinger Health is a Cambridge, Massachusetts-based biotechnology company developing blood-based multi-cancer detection tests under the RESOLVE™ brand, targeting the diagnostic gap between suspicion of cancer and definitive diagnosis. The company's underlying Harbinger HX™ platform combines a developmental biology framework for oncogenesis with cell-free DNA (cfDNA) methylation analysis and proprietary deep learning (ProbeCDN™) to detect early cancer signals and infer tissue of origin across multiple cancer types. The product portfolio includes blood-based assays positioned for symptomatic patients aged 45 and older — a population representing roughly 80% of cancer diagnoses — with clinical evidence showing a positive RESOLVE test raises cancer probability from 74.2% to 98.8% in patients with suspicious imaging findings.
Harbinger HX™ supports modular capabilities including cancer signal detection, tumor content estimation, metastasis prediction, and a low-cost quantitative methylation-specific PCR (qMSP) workflow demonstrated at 97% specificity across nine cancer types. Clinical validation rests on the CORE-HH case-control study (4,137+ participants) and the prospective PROCARES study (88%+ enrolled as of April 2026), with PI oversight from Memorial Sloan Kettering. The laboratory operates as a CLIA-certified, CAP-accredited high-complexity facility enabling in-house test processing.
The company's business model combines direct laboratory testing services for healthcare institutions and cancer care networks with a platform licensing and co-development stream for laboratory, diagnostic, instrument, data, and biopharma partners. Pricing for RESOLVE™ tests is not publicly disclosed. Harbinger Health is wholly backed by Flagship Pioneering, which has provided all $290M of disclosed funding across three rounds (2021, 2023, 2025), and is led by CEO Ajit Singh, Ph.D., with former FDA Commissioner Stephen Hahn serving as CEO Emeritus. First commercial RESOLVE™ products are scheduled for launch in the second half of 2026.
Harbinger Health firmographics
Firmographics- Name
- Harbinger Health
- Legal name
- Harbinger Health
- Website
- https://harbinger-health.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Harbinger Health is a Cambridge-based biotechnology company developing blood-based multi-cancer detection tests (RESOLVE™) that use cfDNA methylation analysis and deep learning to resolve diagnostic uncertainty in symptomatic patients aged 45 and older. The company operates a CLIA-certified laboratory and plans commercial launch in H2 2026.
- Ownership category
- akta.pro rank
Harbinger Health industry classification
Industry- Product category
- Cancer Diagnostics / Liquid Biopsy
- NAICS
- Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
Keywords
Where Harbinger Health is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Harbinger Health business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Blood-based Multi-Cancer Diagnostic Tests (RESOLVE™): Harbinger Health generates revenue through the sale of its RESOLVE™ portfolio of blood-based multi-cancer detection tests. These are diagnostic tests ordered by clinicians for patients presenting with symptoms, signs, or findings suggestive of cancer. The first products are expected to be commercially available in the second half of 2026. Revenue is derived from laboratory testing services billed to healthcare systems, payers, or directly to institutions.
- Platform Licensing and Co-Development (Harbinger HX™): Harbinger Health licenses its Harbinger HX™ platform or co-develops solutions with biopharma, diagnostic, and technology partners. This includes partnerships with laboratory and diagnostic companies, instrument/technology companies, data and analytics platforms, and biopharma partners for biomarker discovery and companion diagnostic development.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | RESOLVE™ diagnostic test pricing is not publicly disclosed |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
Harbinger Health product offering
Product offeringCore offering
Harbinger Health develops and commercializes a portfolio of blood-based multi-cancer detection tests branded as RESOLVE, designed to identify multiple cancers from a single blood draw. The offering is powered by the proprietary Harbinger HX platform, which combines cell-free DNA (cfDNA) methylation analysis with deep learning models, including a deep representation learning framework called ProbeCDN, and is delivered through the company's CLIA-certified clinical laboratory.
Product overview
Harbinger Health offers a platform-plus-products architecture centered on its Harbinger HX™ platform and the RESOLVE™ portfolio of blood-based multi-cancer detection tests. Harbinger HX is an integrated platform combining biology, technology, data, and analytics that analyzes cfDNA methylation patterns using machine learning. RESOLVE™ is a category-defining family of assays built on a single scientific core (cfDNA methylation) designed for different moments when cancer is suspected. The platform supports core capabilities including cancer signal detection, tumor content estimation, and tissue-of-origin inference. The company was founded by Flagship Pioneering and launched in 2020.
Differentiator
Problem solved
Functional benefit
Brands
- RESOLVE™: A new category of blood-based multi-cancer detection tests designed to bring clarity between suspicion of cancer and diagnosis, powered by the Harbinger HX platform.
- Harbinger HX™
Products and services
- RESOLVE multi-cancer detection test A blood-based multi-cancer detection test (part of the RESOLVE portfolio) that uses cfDNA methylation profiling and deep learning to identify multiple cancer signals from a standard blood draw, intended for healthcare providers and clinical use.
Quantifiable outcome
- Test sensitivity of 54.8% (85/155 confirmed cancers) in symptomatic patients with imaging findings suspicious for cancer
- +7 more outcomes
Companies that use Harbinger Health
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Harbinger Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature6 records
Harbinger Health partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered key and supporting.
- Dana-Farber Cancer InstitutekeyDana-Farber Cancer Institute is listed as a partner on Harbinger Health's website. Prof. Franziska Michor, Chief Scientific Advisor & Co-Founder of Harbinger Health, is a Professor of Computational Biology in the Department of Data Science at Dana-Farber Cancer Institute and Harvard. The institute represents a key academic collaboration for clinical research and scientific advisory.
- HCA Healthcare Sarah Cannon Cancer NetworkkeyHCA Healthcare Sarah Cannon Cancer Network is listed as a partner on Harbinger Health's website. Sarah Cannon is one of the world's leading oncology research networks, providing clinical trial infrastructure and patient access for cancer diagnostics development.
- GI AlliancekeyGI Alliance is listed as a partner on Harbinger Health's website. As the nation's largest gastroenterology-focused physician services organization, GI Alliance provides clinical expertise and patient access relevant to gastrointestinal cancer detection applications of the RESOLVE platform.
- YanuviasupportingYanuvia is listed as a partner on Harbinger Health's website. Yanuvia appears as a technology partner providing data and analytics capabilities that may integrate with Harbinger HX platform for signal interpretation and scalable data infrastructure.
- FrazersupportingFrazer and Harbinger are collaborating on developing next-generation mobile healthcare products, as reported in a news brief. The partnership aims to integrate Harbinger's cancer detection technology with mobile healthcare delivery capabilities.
Scale indicators6 records
Recent moves6 records
Expansion highlights7 records
Harbinger Health competitors and assessment
Company assessmentDirect peers
- GRAIL: GRAIL develops Galleri, the most advanced commercial multi-cancer early detection (MCED) blood test using cfDNA methylation. It is the closest direct competitor to Harbinger's RESOLVE, operating in the same cfDNA methylation / early cancer detection category with similar target customers (large healthcare systems, cancer networks).
- Guardant Health: Guardant Health is a leading liquid biopsy company offering cfDNA-based oncology tests (Guardant360, Reveal). It is a direct peer in cfDNA blood-based cancer detection, sharing the same clinical channel (oncologists, hospital systems) and competing for the same ordering physician mindshare. Harbinger's SVP Business Development previously held senior commercial roles at Guardant.
- Natera: Natera develops cell-free DNA-based tests including Signatera for molecular residual disease (MRD) monitoring and tumor-informed assays. It is a direct peer in cfDNA-based oncology diagnostics with established commercial infrastructure and overlapping clinical customers in oncology.
- Freenome: Freenome is developing a blood-based multi-cancer screening test using cfDNA methylation and multi-analyte approaches, targeting similar MCED use cases as Harbinger. It is a direct emerging competitor in the same cfDNA methylation / early detection space with significant venture capital backing.
Broad incumbents
- Exact Sciences: Exact Sciences markets Cologuard (a stool-DNA colorectal cancer screening test built by Harbinger Chief Innovation Officer Tony Shuber) and acquired Thrive Earlier Detection to expand into blood-based MCED. It is a broad incumbent in cancer diagnostics with established commercial scale, payer relationships, and a growing liquid biopsy portfolio directly competitive with Harbinger.
- Tempus AI: Tempus operates a broad AI-driven precision medicine platform spanning oncology genomics, multi-omic profiling, and AI-enabled diagnostics. It is a broad incumbent that competes for the same oncology decision-support and diagnostic-testing spend from healthcare systems and biopharma partners.
- Foundation Medicine: Foundation Medicine (a Roche subsidiary) provides comprehensive genomic profiling of solid tumors via tissue and liquid biopsy. It is a broad incumbent competing for the same oncology diagnostic budgets at major cancer centers and biopharma companies.
Emerging players
- Personalis: Personalis offers cfDNA-based oncology tests including NeXT Personal for MRD detection and tumor-informed liquid biopsy assays. It is an emerging peer with partial overlap in cfDNA-based cancer detection technology and similar customer segments (oncologists, biopharma).
- Caris Life Sciences: Caris offers molecular profiling and AI-driven liquid biopsy assays (e.g., Caris Assure for early detection and MRD). It is an emerging peer in cfDNA-based oncology diagnostics with overlapping capabilities and similar clinical customers.
- Adela: Adela is developing a methylation-based cell-free DNA platform for multi-cancer detection and minimal residual disease monitoring. It is an emerging peer with a closely related cfDNA methylation technology foundation competing for the same early cancer detection opportunity.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Harbinger Health social profiles
Digital presenceHarbinger Health compliance and trust
Trust signalCompliance2 records
Harbinger Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
Harbinger Health leadership team
Management profileNumber of profiles
Profiles17 records
Harbinger Health funding detail
Funding detailFunding overview
Funding rounds3 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Harbinger Health M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Harbinger Health
What does Harbinger Health do?
Harbinger Health develops and commercializes a portfolio of blood-based multi-cancer detection tests branded as RESOLVE, designed to identify multiple cancers from a single blood draw. The offering is powered by the proprietary Harbinger HX platform, which combines cell-free DNA (cfDNA) methylation analysis with deep learning models, including a deep representation learning framework called ProbeCDN, and is delivered through the company's CLIA-certified clinical laboratory.
Is Harbinger Health a public or private company?
Harbinger Health is a private company. It is classified as venture growth investor backed and is currently operating.
When was Harbinger Health founded?
Harbinger Health was founded in 2020. It employs 51 to 100 people.
Where is Harbinger Health based?
Harbinger Health is headquartered in Cambridge, United States, in the North America region.
How does Harbinger Health make money?
Two revenue lines are on record. Blood-based Multi-Cancer Diagnostic Tests (RESOLVE™) is the primary driver. The others are platform Licensing and Co-Development (Harbinger HX™).
Who are Harbinger Health's main competitors?
Direct peers on record are GRAIL, Guardant Health, Natera and Freenome. Broad incumbents are Exact Sciences, Tempus AI and Foundation Medicine. Emerging players are Personalis, Caris Life Sciences and Adela.
Does Harbinger Health have an API?
No public API is recorded for Harbinger Health.
What industry is Harbinger Health in?
Harbinger Health's product category is Cancer Diagnostics / Liquid Biopsy. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 621511 and its SIC code is 2835.